Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.
RLAY · Relay Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 62%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Jul 2020 to Nov 2026
Up next
Latest documents
Relay will present ASH data on all 32 patients from its dose randomization portion, after showing a 60% volumetric response rate across three doses at ISFA in May. Management models five and a half months of median PFS for CAPI. Pfizer supplies termociclib under a clinical trial supply agreement for a frontline trial due to start early next year.
Relay Therapeutics said cash, cash equivalents and investments of $848.6 million as of September 30, 2026 should fund operations into 2029. Nine-month net loss was $238.7 million, while zovegalisib received FDA Breakthrough Therapy designation with fulvestrant.
Relay Therapeutics reported full FDA approval of LYRFIGTU™ (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or other rearrangement, $848.6 million in cash and investments, and zovegalisib trial enrollment expected to complete in mid-2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Relay Therapeutics reported Q2 2026 results with progress across its zovegalisib program: selected the zovegalisib plus atirmociclib triplet as the go-forward 1L breast cancer regimen (Phase 3 expected to start early 2027), presented initial positive Phase 1/2 vascular anomalies data, and raised cash to approximately $911 million providing runway into 2029; R&D spend rose to $76.5M driving a wider net loss of $83.7M.
- + Selected zovegalisib + atirmociclib triplet for 1L breast cancer with Phase 3 expected to initiate early 2027, with Pfizer supplying atirmociclib while Relay retains full global rights to zovegalisib.
- + Reported 44% ORR for the triplet in heavily pretreated (median 3L) HR+/HER2- breast cancer patients at unoptimized doses, with consistent safety profile.
- + Presented initial positive Phase 1/2 ReInspire data in vascular anomalies with 60% volumetric response at 12 weeks, supporting potential chronic use.
- + Cash position grew to approximately $911M (from $642.1M at March 31, 2026) following a $316M follow-on offering, expected to fund operations into 2029.
- + 11-month PFS shown for the doublet in 2L HR+/HER2- breast cancer, viewed by management as meaningfully differentiated versus capivasertib's ~5.5 months, with Phase 3 ReDiscover-2 enrolling.
- − R&D expenses rose to $76.5M in Q2 2026 from $63.9M in Q2 2025, driving a wider net loss of $83.7M.
- − Net loss widened to $83.7M in Q2 2026 from $70.4M in Q2 2025.
- − Revenue declined to $0.4M in Q2 2026 from $0.7M in Q2 2025.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross proceeds from underwritten follow-on public offering | $316M | May 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RLAY
this stock
Relay Therapeutics, Inc.
|
$3.56B | +90.5% | +53.4% | — | 19.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 32
Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RLAY | -10.9% | -11.3% | +2.7% | -12.2% | +90.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -2.3% | -2.1% | +11.9% | -3.4% | +89.4% |